Infectious Diseases

The Infectious Disease Department at St James’s hospital, has a long established research program. The CRF manages a number of both investigator-led and industry centred drug trials in conjunction with the GUIDe clinic.

Current Trials & Studies
Study Name Study TitleStudy TypeSponsorSponsor Type
InoTerm ASTONISH Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study Clinical Trial (NCT04055909) (2018-004827-36)INOTERM S.A Commercial: Industry
MK1439A-028Phase 2b, Double Blinded, Multicentre, Randomized study to assess the effect on central nervous system (CNS) toxicity of switching from Atripla (Efavirenz, tenofovir, emtricatabine) to MK-1439A (Doravine, Tenofovir, lamivudine) in virologically supressed subjectsClinical Trial (NCT02652260) (2015-003617-18)MerckCommercial: Industry
SOLAR studyA Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically SuppressedClinical Trial ( NCT04542070) (2020-002623-11) GSKCommercial: Industry
DiscoverA Phase 3, Randomized, Double-blind study to evaluate the safety and efficacy of emtricitabin and tenofovir alfaenamide (F/AF) Fixed dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV 1 infectionClinical TrialGileadCommercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
Alfa-1A randomized double blind placebo- controlled, pilot trial of intravenous plasma-purified alpha 1 antitrypsin for severe COVID-19 illness Clinical Trial (2020-001391-15) RCSI Non-commercial: Academic
PEACHIPEACHI - A Phase 1 study to assess the safety and immunogenicity of prime boost immunisations with vaccine candidates AdCh3NSmut1 and MVA-Nsmut in HIV-1 seropositive HCV-uninfected adults on antiretroviral therapy (ART)Clinical Trial (NCT02568332)University of OxfordNon-commercial: Academic
GileadA phase 3b, Randomized, Double Blind, swithc study to evaluate F/TAF in HIV-1 infected Subjects who are virologically suppressed on regimens containing ABC/3TCClinical Trial (NCT02469246)GileadCommercial: Industry
COGHIVThe effects of a 16 week aerobic exercise programme on cognitive function in people living with HIV: A Radnomised Controlled TrialObservational-non invasiveN/ANon-commercial: Academic
COGIMPThe Inflammatory Neurodegenerative Continuum in HIV Related Cognitive Impairment. Longitudinal Follow up of Cognitive Impairment in a Well Characterized Cohort of HIV Positive PatientsObservational-non invasiveN/ANon-commercial: Academic